Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Physical activity in patients with chronic kidney disease (including end-stage renal disease and renal transplantation)

Brent W Miller, MD
Section Editor
Daniel C Brennan, MD, FACP
Deputy Editor
Albert Q Lam, MD


Exercise rehabilitation has been extensively utilized for patients with severe cardiac, pulmonary, and neurologic diseases. Patients with chronic kidney disease (CKD), as well as those with a functional renal allograft, also have physiologic abnormalities that require physical rehabilitation for optimal health [1]. This topic will discuss the underlying causes and treatment of deconditioning in patients with CKD and renal transplant recipients. (See "The benefits and risks of exercise".)


Causes of deconditioning among patients with CKD and renal transplant recipients may include:

Comorbid conditions, including diabetes, cardiac disease, and peripheral vascular disease

Recurrent hospitalization episodes

Uremic myopathy and/or neuropathy (see "Uremic mononeuropathy" and "Uremic polyneuropathy")


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jul 13, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Johansen KL. Exercise in the end-stage renal disease population. J Am Soc Nephrol 2007; 18:1845.
  2. Johansen KL, Chertow GM, Ng AV, et al. Physical activity levels in patients on hemodialysis and healthy sedentary controls. Kidney Int 2000; 57:2564.
  3. Painter P. Physical functioning in end-stage renal disease patients: update 2005. Hemodial Int 2005; 9:218.
  4. Hsieh RL, Lee WC, Chang CH. Maximal cardiovascular fitness and its correlates in ambulatory hemodialysis patients. Am J Kidney Dis 2006; 48:21.
  5. DeGowin RL, Lavender AR, Forland M, et al. Erythropoiesis and erythropoietin in patients with chronic renal failure treated with hemodialysis and testosterone. Ann Intern Med 1970; 72:913.
  6. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281:1275.
  7. Johansen KL, Painter PL, Sakkas GK, et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol 2006; 17:2307.
  8. Guthrie M, Cardenas D, Eschbach JW, et al. Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol 1993; 39:97.
  9. Davenport A. The effect of treatment with recombinant human erythropoietin on skeletal muscle function in patients with end-stage renal failure treated with regular hospital hemodialysis. Am J Kidney Dis 1993; 22:685.
  10. Davenport A, King RF, Ironside JW, et al. The effect of treatment with recombinant human erythropoietin on the histological appearance and glycogen content of skeletal muscle in patients with chronic renal failure treated by regular hospital haemodialysis. Nephron 1993; 64:89.
  11. Thompson CH, Kemp GJ, Taylor DJ, et al. No effect of blood transfusion on muscle metabolism. Q J Med 1992; 85:897.
  12. Leikis MJ, McKenna MJ, Petersen AC, et al. Exercise performance falls over time in patients with chronic kidney disease despite maintenance of hemoglobin concentration. Clin J Am Soc Nephrol 2006; 1:488.
  13. Prabhala A, Garg R, Dandona P. Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med 2000; 160:1199.
  14. Hewitt NA, O'Connor AA, O'Shaughnessy DV, Elder GJ. Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8:1143.
  15. Llach F, Prados MD, Hervas J, et al. Vitamin D insufficiency and secondary hyperparathyroidism in 210 patients with CKD 2, 3, and 4 (abstract). J Am Soc Nephrol 2005; 16:756A.
  16. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003; 78:1463.
  17. Ureña P, Kong XF, Abou-Samra AB, et al. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology 1993; 133:617.
  18. Ritz E, Stefanski A, Rambausek M. The role of the parathyroid glands in the uremic syndrome. Am J Kidney Dis 1995; 26:808.
  19. Chou FF, Lee CH, Chen JB. General weakness as an indication for parathyroid surgery in patients with secondary hyperparathyroidism. Arch Surg 1999; 134:1108.
  20. Joborn C, Rastad J, Stålberg E, et al. Muscle function in patients with primary hyperparathyroidism. Muscle Nerve 1989; 12:87.
  21. Tawney KW, Dinwiddie L, et al. Changes in upper extremity function associated with vascular access creation. J Am Soc Nephrol 2001; 12:251A.
  22. Oder TF, Teodorescu V, Uribarri J. Effect of exercise on the diameter of arteriovenous fistulae in hemodialysis patients. ASAIO J 2003; 49:554.
  23. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002; 13:708.
  24. Kopple JD. The rationale for the use of growth hormone or insulin-like growth factor I in adult patients with renal failure. Miner Electrolyte Metab 1992; 18:269.
  25. Johannsson G, Bengtsson BA, Ahlmén J. Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 1999; 33:709.
  26. Iglesias P, Díez JJ. Recombinant human growth hormone therapy in adult dialysis patients. Int J Artif Organs 2000; 23:802.
  27. Kopple JD, Cheung AK, Christiansen JS, et al. OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant 2011; 26:4095.
  28. Diesel W, Emms M, Knight BK, et al. Morphologic features of the myopathy associated with chronic renal failure. Am J Kidney Dis 1993; 22:677.
  29. Moore GE, Parsons DB, Stray-Gundersen J, et al. Uremic myopathy limits aerobic capacity in hemodialysis patients. Am J Kidney Dis 1993; 22:277.
  30. Campistol JM. Uremic myopathy. Kidney Int 2002; 62:1901.
  31. Sun DF, Chen Y, Rabkin R. Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia. Kidney Int 2006; 70:453.
  32. Johansen KL, Shubert T, Doyle J, et al. Muscle atrophy in patients receiving hemodialysis: effects on muscle strength, muscle quality, and physical function. Kidney Int 2003; 63:291.
  33. Clyne N, Esbjörnsson M, Jansson E, et al. Effects of renal failure on skeletal muscle. Nephron 1993; 63:395.
  34. Painter P, Taylor J, Wolcott S, et al. Exercise capacity and muscle structure in kidney recipient and twin donor. Clin Transplant 2003; 17:225.
  35. Isoyama N, Qureshi AR, Avesani CM, et al. Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin J Am Soc Nephrol 2014; 9:1720.
  36. Painter P, Carlson L, Carey S, et al. Physical functioning and health-related quality-of-life changes with exercise training in hemodialysis patients. Am J Kidney Dis 2000; 35:482.
  37. Lo CY, Li L, Lo WK, et al. Benefits of exercise training in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1998; 32:1011.
  38. DePaul V, Moreland J, Eager T, Clase CM. The effectiveness of aerobic and muscle strength training in patients receiving hemodialysis and EPO: a randomized controlled trial. Am J Kidney Dis 2002; 40:1219.
  39. Mustata S, Chan C, Lai V, Miller JA. Impact of an exercise program on arterial stiffness and insulin resistance in hemodialysis patients. J Am Soc Nephrol 2004; 15:2713.
  40. van Vilsteren MC, de Greef MH, Huisman RM. The effects of a low-to-moderate intensity pre-conditioning exercise programme linked with exercise counselling for sedentary haemodialysis patients in The Netherlands: results of a randomized clinical trial. Nephrol Dial Transplant 2005; 20:141.
  41. Cheema B, Abas H, Smith B, et al. Randomized controlled trial of intradialytic resistance training to target muscle wasting in ESRD: the Progressive Exercise for Anabolism in Kidney Disease (PEAK) study. Am J Kidney Dis 2007; 50:574.
  42. Clyne N. The importance of exercise training in predialysis patients with chronic kidney disease. Clin Nephrol 2004; 61 Suppl 1:S10.
  43. Boyce ML, Robergs RA, Avasthi PS, et al. Exercise training by individuals with predialysis renal failure: cardiorespiratory endurance, hypertension, and renal function. Am J Kidney Dis 1997; 30:180.
  44. Castaneda C, Gordon PL, Uhlin KL, et al. Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Med 2001; 135:965.
  45. Sakkas GK, Sargeant AJ, Mercer TH, et al. Changes in muscle morphology in dialysis patients after 6 months of aerobic exercise training. Nephrol Dial Transplant 2003; 18:1854.
  46. Birdee GS, Bossart C, Wheeler A, et al. Development of an intra-dialysis yoga protocol for patients with end-stage renal disease. Yoga Phys Ther 2015; 5:186.
  47. Giannaki CD, Hadjigeorgiou GM, Karatzaferi C, et al. A single-blind randomized controlled trial to evaluate the effect of 6 months of progressive aerobic exercise training in patients with uraemic restless legs syndrome. Nephrol Dial Transplant 2013; 28:2834.
  48. Greenwood SA, Koufaki P, Mercer TH, et al. Effect of exercise training on estimated GFR, vascular health, and cardiorespiratory fitness in patients with CKD: a pilot randomized controlled trial. Am J Kidney Dis 2015; 65:425.
  49. Robinson-Cohen C, Littman AJ, Duncan GE, et al. Physical activity and change in estimated GFR among persons with CKD. J Am Soc Nephrol 2014; 25:399.
  50. Chen IR, Wang SM, Liang CC, et al. Association of walking with survival and RRT among patients with CKD stages 3-5. Clin J Am Soc Nephrol 2014; 9:1183.
  51. Stack AG, Molony DA, Rives T, et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 2005; 45:690.
  52. Lopes AA, Lantz B, Morgenstern H, et al. Associations of self-reported physical activity types and levels with quality of life, depression symptoms, and mortality in hemodialysis patients: the DOPPS. Clin J Am Soc Nephrol 2014; 9:1702.
  53. Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. Am J Kidney Dis 2014; 64:383.
  54. Painter P, Hanson P, Messer-Rehak D, et al. Exercise tolerance changes following renal transplantation. Am J Kidney Dis 1987; 10:452.
  55. Bohannon RW, Hull D, Palmeri D. Muscle strength impairments and gait performance deficits in kidney transplantation candidates. Am J Kidney Dis 1994; 24:480.
  56. Bohannon RW, Smith J, Hull D, et al. Deficits in lower extremity muscle and gait performance among renal transplant candidates. Arch Phys Med Rehabil 1995; 76:547.
  57. Kempeneers G, Noakes TD, van Zyl-Smit R, et al. Skeletal muscle limits the exercise tolerance of renal transplant recipients: effects of a graded exercise training program. Am J Kidney Dis 1990; 16:57.
  58. Painter P. Exercise after renal transplantation. Adv Ren Replace Ther 1999; 6:159.
  59. Horber FF, Hoppeler H, Herren D, et al. Altered skeletal muscle ultrastructure in renal transplant patients on prednisone. Kidney Int 1986; 30:411.
  60. PERKOFF GT, SILBER R, TYLER FH, et al. Studies in disorders of muscle. XII. Myopathy due to the administration of therapeutic amounts of 17-hydroxycorticosteroids. Am J Med 1959; 26:891.
  61. Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 1983; 18:155.
  62. Cushing H. Basophil adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 1932; 50:137.
  63. Topp KS, Painter PL, Walcott S, et al. Alterations in skeletal muscle structure are minimized with steroid withdrawal after renal transplantation. Transplantation 2003; 76:667.
  64. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005; 5:2473.
  65. Horber FF, Scheidegger JR, Grünig BE, Frey FJ. Thigh muscle mass and function in patients treated with glucocorticoids. Eur J Clin Invest 1985; 15:302.
  66. Kobashigawa JA, Leaf DA, Lee N, et al. A controlled trial of exercise rehabilitation after heart transplantation. N Engl J Med 1999; 340:272.
  67. Miller BW, Cress CL, Johnson ME, et al. Exercise during hemodialysis decreases the use of antihypertensive medications. Am J Kidney Dis 2002; 39:828.
  68. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.